Speiser Daniel E, Baumgaertner Petra, Voelter Verena, Devevre Estelle, Barbey Catherine, Rufer Nathalie, Romero Pedro
Division of Clinical Onco-Immunology, Ludwig Institute for Cancer Research and University of Lausanne, and Multidisciplinary Oncology Center, Centre Hospitalier Universitaire Vaudois, 1001 Lausanne, Switzerland.
Proc Natl Acad Sci U S A. 2008 Mar 11;105(10):3849-54. doi: 10.1073/pnas.0800080105. Epub 2008 Mar 4.
Human cancer vaccines are often prepared with altered "analog" or "heteroclitic" antigens that have been optimized for HLA class I binding, resulting in enhanced immunogenicity. Here, we take advantage of CpG oligodeoxynucleotides as powerful vaccine adjuvants and demonstrate the induction of high T cell frequencies in melanoma patients, despite the use of natural (unmodified) tumor antigenic peptide. Compared with vaccination with analog peptide, natural peptide induced T cell frequencies that were approximately twofold lower. However, T cells showed superior tumor reactivity because of (i) increased functional avidity for natural antigen and (ii) enhancement of T cell activation and effector function. Thus, novel vaccine formulations comprising potent immune stimulators may allow to circumvent the need for modified antigens and can induce highly functional T cells with precise antigen specificity.
人类癌症疫苗通常采用经过改变的“类似物”或“异质性”抗原制备,这些抗原已针对HLA I类结合进行了优化,从而增强了免疫原性。在此,我们利用CpG寡脱氧核苷酸作为强大的疫苗佐剂,证明了在黑色素瘤患者中可诱导产生高频率的T细胞,尽管使用的是天然(未修饰)肿瘤抗原肽。与使用类似物肽进行疫苗接种相比,天然肽诱导的T细胞频率大约低两倍。然而,T细胞显示出更强的肿瘤反应性,原因如下:(i)对天然抗原的功能亲和力增加;(ii)T细胞活化和效应功能增强。因此,包含强效免疫刺激剂的新型疫苗制剂可能无需使用修饰抗原,并能诱导出具有精确抗原特异性的高功能T细胞。